who owns ozempic

Novo Nordisk owns Ozempic. Specifically, Novo Nordisk develops and markets Ozempic (semaglutide) for diabetes, alongside Wegovy for obesity, under the umbrella of Novo Nordisk A/S. The company is controlled by its majority shareholder, Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation), which holds a large portion of voting rights. If you’d like, I can pull up the latest corporate governance details or recent board developments related to Ozempic’s ownership structure and the role of the Novo Nordisk Foundation.